Cytisine
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-CYTISINE |
|---|---|
| Type | Drug |
| Aliases | CytisiniclineDesmoxanTabexЦитизин |
| Status | reviewed 2026-05-18 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 |
Drug Facts
| Class | α4β2 nicotinic acetylcholine receptor partial agonist (plant alkaloid from Cytisus laburnum) |
|---|---|
| Mechanism | Naturally-occurring plant alkaloid; partial agonist at α4β2 nicotinic acetylcholine receptor (same target as varenicline, of which it is the structural prototype). Produces modest dopaminergic activation (relieving craving/withdrawal) while blocking nicotine binding. Has been used as tobacco-cessation pharmacotherapy in Eastern Europe since the 1960s; comparative trials (e.g., RAUORA 2021, CASCAID) suggest efficacy comparable to varenicline at lower cost. |
| Typical dosing | PO: tapered 25-day course (standard Tabex protocol): Days 1-3: 1 tablet (1.5 mg) every 2 h (max 6/day) Days 4-12: 1 tablet every 2.5 h (max 5/day) Days 13-16: 1 tablet every 3 h (max 4/day) Days 17-20: 1 tablet every 5 h (max 3/day) Days 21-25: 1-2 tablets/day Quit date typically by day 5. Reducing-frequency dosing limits adherence. |
| Ukraine registered | True |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-05-18 |
Notes
STUB — v0.2 prevention-workstream authoring; pending two-Clinical-Co-Lead signoff per CHARTER §6.1 dev-mode. Alternative to varenicline, primarily used outside USA. Originating compound for varenicline development. Tabex widely available + inexpensive in Ukraine and Central/Eastern Europe. Tapered 25-day dosing limits real-world adherence vs. simpler varenicline regimen. Source cited (SRC-NCCN-BCELL-2025) is closest in-KB until cytisine-specific (RAUORA, CASCAID, Cochrane) sources land in source-stub workstream.
Used By
No reverse references found in the YAML corpus.